These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 26657199)
41. Nanomedicine strategies for hematological malignancies: what is next? Visani G; Loscocco F; Isidori A Nanomedicine (Lond); 2014 Oct; 9(15):2415-28. PubMed ID: 25413858 [TBL] [Abstract][Full Text] [Related]
42. Acute generalized exanthematous pustulosis induced by sorafenib. Pretel M; Iñarrairaegui M; Lera JM; Aguado L; Idoate MA JAMA Dermatol; 2014 Jun; 150(6):664-6. PubMed ID: 24671701 [No Abstract] [Full Text] [Related]
43. [Chinese herbal drugs: sheng-bai-kuai in the treatment of leukopenia caused by chemotherapy]. Tan D; Xie ZZ; Zhong M; Wu D; Liang X; Li W; Qin Q; Tam G Hunan Yi Ke Da Xue Xue Bao; 1997; 22(6):547-9. PubMed ID: 10073005 [No Abstract] [Full Text] [Related]
44. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Kelly WK; Richon VM; O'Connor O; Curley T; MacGregor-Curtelli B; Tong W; Klang M; Schwartz L; Richardson S; Rosa E; Drobnjak M; Cordon-Cordo C; Chiao JH; Rifkind R; Marks PA; Scher H Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3578-88. PubMed ID: 14506144 [TBL] [Abstract][Full Text] [Related]
50. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response. Vena F; Hartley JA; Hochhauser D Clin Cancer Res; 2016 May; 22(10):2595. PubMed ID: 27179114 [No Abstract] [Full Text] [Related]
51. Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies. Vahid B; Marik PE Can Respir J; 2008; 15(4):211-6. PubMed ID: 18551203 [TBL] [Abstract][Full Text] [Related]
52. [Advances of targeted therapy in treatment of hematologic malignancies]. Huang H; Cao WJ Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 36(4):313-8. PubMed ID: 17717819 [No Abstract] [Full Text] [Related]
53. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter. Leon LG; Funel N; Peters GJ; Avan A; Vistoli F; Boggi U; Giovannetti E Clin Cancer Res; 2016 May; 22(10):2594. PubMed ID: 27179113 [No Abstract] [Full Text] [Related]
54. Sperm cryopreservation in patients with hematologic malignancies. Meguro A; Muroi K; Miyoshi T; Matsuyama T; Mori M; Nagai T; Ozawa K Int J Hematol; 2008 Oct; 88(3):351-354. PubMed ID: 18696184 [No Abstract] [Full Text] [Related]
55. Postchemotherapy connective tissue diseases--more than just rheumatism? Amft N; D'Cruz D Lupus; 1996 Aug; 5(4):255-6. PubMed ID: 8869893 [No Abstract] [Full Text] [Related]
56. The intensive care support of patients with malignancy: do everything that can be done. Azoulay E; Afessa B Intensive Care Med; 2006 Jan; 32(1):3-5. PubMed ID: 16308682 [No Abstract] [Full Text] [Related]
57. [Traceability of oncohematological drugs through data capture codes]. Escudero-Vilaplana B; Manso-Manrique M; García-Sanz E; Sánchez-Guerrero A Farm Hosp; 2017 Sep; 41(5):649-650. PubMed ID: 28847260 [No Abstract] [Full Text] [Related]
58. Translational hematology. Geissler K Wien Med Wochenschr; 2014 Nov; 164(21-22):487-96. PubMed ID: 25205187 [TBL] [Abstract][Full Text] [Related]
59. [Emergency in pediatric hematologic oncology. French Group for the Study of Cancers and Leukemias of the Child (CFECLE)]. Leverger G; Sommelet D Arch Pediatr; 1999; 6 Suppl 2():459s-460s. PubMed ID: 10370569 [No Abstract] [Full Text] [Related]
60. [What are the limits of the indications and applications of major therapies?: The example of anticancer chemotherapy]. Casassus P Therapie; 2004; 59(2):243-5. PubMed ID: 15359621 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]